Camille Azam1, Louis Buscail2, Adrian Culetto3, Maryse Lapeyre-Mestre4. 1. Service de Pharmacologie Médicale et Clinique, Faculté de Médecine, CIC 1436, CHU, Université de Toulouse, 37 allées Jules Guesde, 31000, Toulouse, France. 2. Service de Gastroentérologie et Pancréatologie, CIC Biotherapies 1436, CHU, Université de Toulouse, Toulouse, France. 3. Service de Gastroentérologie et Pancréatologie, CHU, Université de Toulouse, Toulouse, France. 4. Service de Pharmacologie Médicale et Clinique, Faculté de Médecine, CIC 1436, CHU, Université de Toulouse, 37 allées Jules Guesde, 31000, Toulouse, France. maryse.lapeyre-mestre@univ-tlse3.fr.
Abstract
INTRODUCTION: In addition to the growing interest of different cannabinoids for therapeutic purposes, the safety profile of these substances has changed, with the recent identification of new events such as acute pancreatitis. OBJECTIVE: The aim of this study was to characterize cannabinoid-related acute pancreatitis, based on the recent literature and the analysis of pharmacovigilance data available worldwide. METHODS: Nine national and international pharmacovigilance databases were requested for individual case safety reports of acute pancreatitis related to cannabinoid exposure. A systematic review was performed searching in PubMed®, Web of Science®, and Google Scholar® for any publication dealing with acute pancreatitis and cannabinoid exposure (cannabis, cannabinoid, cannabidiol, tetrahydrocannabinol, nabilone, dronabinol), to identify case reports, observational studies, clinical trials, or reviews. All queries were updated on 1 January, 2021. RESULTS: Twenty-two individual case safety reports were identified in the pharmacovigilance databases and 51 in the literature, corresponding to a predominantly young male population (74% of men, median age 28 interquartile range [21-39]) using recreational Cannabis sativa with high intensity. A therapeutic purpose was identified in 13 cases (including tetrahydrocannabinol, cannabidiol, and dronabinol). The outcome was often favorable after dechallenge (except three deaths), and frequent recurrences were observed in the case of rechallenge or sustained consumption. Eleven cross-sectional studies and one ecological study showed an increasing trend of cannabis use in in-patients with acute pancreatitis, with a significantly lower in-hospital mortality. CONCLUSIONS: This review underlines that acute pancreatitis is a potential adverse effect of cannabinoid use. It remains often unrecognized and can occur during recreational or therapeutic use. The development of the therapeutic use of cannabinoids in frail patients deserves a better investigation of the benefit-risk ratio of these different products.
INTRODUCTION: In addition to the growing interest of different cannabinoids for therapeutic purposes, the safety profile of these substances has changed, with the recent identification of new events such as acute pancreatitis. OBJECTIVE: The aim of this study was to characterize cannabinoid-related acute pancreatitis, based on the recent literature and the analysis of pharmacovigilance data available worldwide. METHODS: Nine national and international pharmacovigilance databases were requested for individual case safety reports of acute pancreatitis related to cannabinoid exposure. A systematic review was performed searching in PubMed®, Web of Science®, and Google Scholar® for any publication dealing with acute pancreatitis and cannabinoid exposure (cannabis, cannabinoid, cannabidiol, tetrahydrocannabinol, nabilone, dronabinol), to identify case reports, observational studies, clinical trials, or reviews. All queries were updated on 1 January, 2021. RESULTS: Twenty-two individual case safety reports were identified in the pharmacovigilance databases and 51 in the literature, corresponding to a predominantly young male population (74% of men, median age 28 interquartile range [21-39]) using recreational Cannabis sativa with high intensity. A therapeutic purpose was identified in 13 cases (including tetrahydrocannabinol, cannabidiol, and dronabinol). The outcome was often favorable after dechallenge (except three deaths), and frequent recurrences were observed in the case of rechallenge or sustained consumption. Eleven cross-sectional studies and one ecological study showed an increasing trend of cannabis use in in-patients with acute pancreatitis, with a significantly lower in-hospital mortality. CONCLUSIONS: This review underlines that acute pancreatitis is a potential adverse effect of cannabinoid use. It remains often unrecognized and can occur during recreational or therapeutic use. The development of the therapeutic use of cannabinoids in frail patients deserves a better investigation of the benefit-risk ratio of these different products.
Authors: Elaina Vivian; Leslie Cler; Darwin Conwell; Gregory A Coté; Richard Dickerman; Martin Freeman; Timothy B Gardner; Robert H Hawes; Prashant Kedia; Rajesh Krishnamoorthi; Hellen Oduor; Stephen J Pandol; Georgios I Papachristou; Andrew Ross; Amrita Sethi; Shyam Varadarajulu; Santhi Swaroop Vege; Wahid Wassef; C Mel Wilcox; David C Whitcomb; Bechien U Wu; Dhiraj Yadav; Ashton Ellison; Samar Habash; Sheila Rastegari; Rathan Reddy; Timothy Yen; Mary Rachel Brooks; Paul Tarnasky Journal: Am J Gastroenterol Date: 2019-08 Impact factor: 10.864
Authors: Thomas Berbain; Antoine Pariente; Ghada Miremont-Salamé; Aurélie Grandvuillemin; Joelle Micallef; Laurent Chouchana; Mehdi Benkebil; Hélène Théophile Journal: Drug Saf Date: 2020-03 Impact factor: 5.606
Authors: Ágnes Meczker; Lilla Hanák; Andrea Párniczky; Andrea Szentesi; Bálint Erőss; Péter Hegyi Journal: Gastroenterology Date: 2020-07-17 Impact factor: 22.682
Authors: Matthew J Page; Joanne E McKenzie; Patrick M Bossuyt; Isabelle Boutron; Tammy C Hoffmann; Cynthia D Mulrow; Larissa Shamseer; Jennifer M Tetzlaff; Elie A Akl; Sue E Brennan; Roger Chou; Julie Glanville; Jeremy M Grimshaw; Asbjørn Hróbjartsson; Manoj M Lalu; Tianjing Li; Elizabeth W Loder; Evan Mayo-Wilson; Steve McDonald; Luke A McGuinness; Lesley A Stewart; James Thomas; Andrea C Tricco; Vivian A Welch; Penny Whiting; David Moher Journal: Syst Rev Date: 2021-03-29